Back to search

Article

Efficacy and Safety of the use of Pertuzumab in Metastatic Breast Cancer Patients in a Real-World Setting: Results from the SUPER-GONO (Gruppo Oncologico del Nord Ovest) Study

2021-04-14

Abstract excerpt

<title>Abstract</title> <p><bold><italic>Background:</italic></bold><italic> </italic>Real world data have the potential to demonstrate the applicability of the results of randomized studies in the general population. SUPER trial was conducted in order to assess the activity, the efficacy and the safety of the combination of pertuzumab, trastuzumab and chemotherapy in clinical practice.<bold><italic>Material and...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
7538005c-e6a5-520c-9412-b413a7f6896e
DOI
10.21203/rs.3.rs-409228/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Efficacy and Safety of the use of Pertuzumab in Metastatic Breast Cancer Patients in a Real-World Setting: Results from the SUPER-GONO (Gruppo Oncologico del Nord Ovest) StudyDOI 10.21203/rs.3.rs-409228/v1
The Efficacy and Safety of Sacituzumab Govitecan in Heavily Pretreated Metastatic Triple-Negative and Hormone Receptor-Positive/HER2-Negative Breast Cancer: A Multicenter Real-World Study from TurkeySemantic proximity
Real-World Treatment Patterns and Outcomes in Elderly Patients with Metastatic Breast Cancer: A Multi- institutional Retrospective Cohort StudySemantic proximity
Real-world data of eribulin in advanced and pretreated HER2-negative breast cancer in a Spanish comprehensive cancer centerSemantic proximity
Comparison of Targeted Therapy Efficacy in HER2-Positive Versus HER2-Negative Breast Cancer PatientsSemantic proximity
Real-World Outcomes of CDK4/6 Inhibitors in Germline BRCA-Mutated Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) StudySemantic proximity
Oral etoposide and trastuzumab in HER2-positive metastatic breast cancer: a retrospective study at Institut Curie Hospitals.Semantic proximity
Real-World Outcomes of Subcutaneous PHESGO® in HER2-Positive Breast Cancer: Pathological Response, Se-Quencing, and SafetySemantic proximity
The efficacy and safety of pyrotinib in treating HER2-positive metastatic breast cancer patients:A multi-center studySemantic proximity
Anthracycline-Free Neoadjuvant Treatment in Patients with HER2-Positive Breast Cancer: Real-Life Use of Pertuzumab, Trastuzumab and Taxanes Association with an Exploratory Analysis of PIK3CA Mutational StatusSemantic proximity
Facts and controversies in the use of trastuzumab in the adjuvant setting.Semantic proximity
Tolerability of Eribulin and Correlation Between Polymorphisms and Neuropathy in an Unselected Population of Female Patients with Metastatic Breast Cancer: Results of The Multicenter, Single Arm, Phase IV PAINTER StudySemantic proximity
Pertuzumab Plus Trastuzumab in Patients With Endometrial Cancer With ERBB2/3 Amplification, Overexpression, or Mutation: Results From the TAPUR Study.Semantic proximity
Select a neighboring publication to make it the new centre.